Nls Pharmaceutics Ag Stock Probability of Future Stock Price Finishing Under 0.0152
| NLSPW Stock | USD 0.02 0.0001 0.62% |
NLS |
NLS Pharmaceutics Target Price Odds to finish below 0.0152
The tendency of NLS Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.02 or more in 90 days |
| 0.02 | 90 days | 0.02 | about 58.71 |
Based on a normal probability distribution, the odds of NLS Pharmaceutics to drop to $ 0.02 or more in 90 days from now is about 58.71 (This NLS Pharmaceutics AG probability density function shows the probability of NLS Stock to fall within a particular range of prices over 90 days) . Probability of NLS Pharmaceutics price to stay between $ 0.02 and its current price of $0.0159 at the end of the 90-day period is about 6.56 .
Assuming the 90 days horizon NLS Pharmaceutics AG has a beta of -4.22. This indicates as returns on its benchmark rise, returns on holding NLS Pharmaceutics AG are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, NLS Pharmaceutics is expected to outperform its benchmark. In addition to that NLS Pharmaceutics AG has an alpha of 5.0672, implying that it can generate a 5.07 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). NLS Pharmaceutics Price Density |
| Price |
Predictive Modules for NLS Pharmaceutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as NLS Pharmaceutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.NLS Pharmaceutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. NLS Pharmaceutics is not an exception. The market had few large corrections towards the NLS Pharmaceutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold NLS Pharmaceutics AG, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of NLS Pharmaceutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 5.07 | |
β | Beta against Dow Jones | -4.22 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.13 |
NLS Pharmaceutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of NLS Pharmaceutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for NLS Pharmaceutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| NLS Pharmaceutics is way too risky over 90 days horizon | |
| NLS Pharmaceutics has some characteristics of a very speculative penny stock | |
| NLS Pharmaceutics appears to be risky and price may revert if volatility continues | |
| NLS Pharmaceutics has high likelihood to experience some financial distress in the next 2 years | |
| NLS Pharmaceutics AG has accumulated 1.63 M in total debt. NLS Pharmaceutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about NLS Pharmaceutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (12.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NLS Pharmaceutics AG has accumulated about 145.4 K in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| NLS Pharmaceutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from accesswire.com: NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists in Narcolepsy and Neurological Disorders |
NLS Pharmaceutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of NLS Stock often depends not only on the future outlook of the current and potential NLS Pharmaceutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NLS Pharmaceutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 38.2 M | |
| Cash And Short Term Investments | 897.7 K |
NLS Pharmaceutics Technical Analysis
NLS Pharmaceutics' future price can be derived by breaking down and analyzing its technical indicators over time. NLS Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of NLS Pharmaceutics AG. In general, you should focus on analyzing NLS Stock price patterns and their correlations with different microeconomic environments and drivers.
NLS Pharmaceutics Predictive Forecast Models
NLS Pharmaceutics' time-series forecasting models is one of many NLS Pharmaceutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary NLS Pharmaceutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about NLS Pharmaceutics
Checking the ongoing alerts about NLS Pharmaceutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for NLS Pharmaceutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| NLS Pharmaceutics is way too risky over 90 days horizon | |
| NLS Pharmaceutics has some characteristics of a very speculative penny stock | |
| NLS Pharmaceutics appears to be risky and price may revert if volatility continues | |
| NLS Pharmaceutics has high likelihood to experience some financial distress in the next 2 years | |
| NLS Pharmaceutics AG has accumulated 1.63 M in total debt. NLS Pharmaceutics has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about NLS Pharmaceutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (12.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NLS Pharmaceutics AG has accumulated about 145.4 K in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| NLS Pharmaceutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from accesswire.com: NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists in Narcolepsy and Neurological Disorders |
Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.